Trevi Therapeutics’ $50 Million Series C Round Funding

Cooley advised New Enterprise Associates (NEA) on leading Trevi Therapeutics’ $50.5 million Series C financing round.

The financing round included new investors Lundbeckfonden Ventures, Omega Funds, Aperture Venture Partners and TPG Biotech.

According to Trevi, the funds will be used to advance the development of Nalbuphine ER, a drug with a dual agonist/antagonist mechanism of action uniquely suited to treating itch associated in various dermatologic, metabolic, hematologic and neuropathic conditions.

As one of the world’s largest and most active venture capital firms, NEA has developed deep domain expertise and insight into its industries of focus. It channels that knowledge into every technology and healthcare investment it makes – at any stage, in any location, around the globe.

Cooley advised with a team including Ryan Sansom, Margaret Siegel and Div Gupta (Picture).

Involved fees earner: Ryan Sansom – Cooley LLP; Margaret Siegel – Cooley LLP; Div Gupta – Cooley LLP;

Law Firms: Cooley LLP;

Clients: New Enterprise Associates;


Author: Ambrogio Visconti